Literature DB >> 17255465

Effects of muscarinic M1 receptor blockade on cocaine-induced elevations of brain dopamine levels and locomotor behavior in rats.

Gianluigi Tanda1, Aaron L Ebbs, Theresa A Kopajtic, Lyn M Elias, Bettye L Campbell, Amy H Newman, Jonathan L Katz.   

Abstract

Cholinergic muscarinic systems have been shown to influence dopaminergic function in the central nervous system. In addition, previous studies of benztropine analogs that inhibit dopamine uptake and show antagonism at muscarinic receptors show these drugs to be less effective than cocaine in producing its various prototypic effects such as locomotor stimulation. Because previous pharmacological studies on these topics have used nonselective M1 antagonists, we examined the interactions of preferential M1 muscarinic antagonists and cocaine. Dose-dependent increases in extracellular levels of dopamine in selected brain areas, the nucleus accumbens (NAc) shell and core, and the prefrontal cortex, were produced by cocaine but not by the preferential M1 antagonists telenzepine and trihexyphenidyl. When administered with cocaine, however, both M1 antagonists dose-dependently increased the effects of cocaine on dopamine in the NAc shell, and these effects were selective in that they were not obtained in the NAc core or in the prefrontal cortex. Telenzepine also increased locomotor activity, although the effect was small compared with that of cocaine. The locomotor stimulant effects of trihexyphenidyl, in contrast, approached those of cocaine. Telenzepine attenuated, whereas trihexyphenidyl enhanced the locomotor stimulant effects of cocaine, with neither drug facilitating cocaine-induced stereotypy. The present results indicate that preferential antagonist effects at muscarinic M1 receptors do not uniformly alter all of the effects of cocaine, nor do they explain the differences in effects of cocaine and benztropine analogs, and that the alterations in dopamine levels in the NAc shell do not predict the behavioral effects of the interactions with cocaine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17255465     DOI: 10.1124/jpet.106.118067

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

1.  Preference for distinct functional conformations of the dopamine transporter alters the relationship between subjective effects of cocaine and stimulation of mesolimbic dopamine.

Authors:  Stephen J Kohut; Takato Hiranita; Soo-Kyung Hong; Aaron L Ebbs; Valeria Tronci; Jennifer Green; Linda Garcés-Ramírez; Lauren E Chun; Maddalena Mereu; Amy H Newman; Jonathan L Katz; Gianluigi Tanda
Journal:  Biol Psychiatry       Date:  2014-04-19       Impact factor: 13.382

2.  The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse.

Authors:  Ahmed A Othman; Amy H Newman; Natalie D Eddington
Journal:  J Pharm Sci       Date:  2008-12       Impact factor: 3.534

Review 3.  Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions.

Authors:  Kalynda K Gonzales; Yoland Smith
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

4.  Locomotor activating effects of cocaine and scopolamine combinations in rats: isobolographic analysis.

Authors:  Morgane Thomsen
Journal:  Behav Pharmacol       Date:  2014-08       Impact factor: 2.293

5.  Effects of muscarinic receptor antagonists on cocaine discrimination in wild-type mice and in muscarinic receptor M1, M2, and M4 receptor knockout mice.

Authors:  Lauren Joseph; Morgane Thomsen
Journal:  Behav Brain Res       Date:  2017-04-22       Impact factor: 3.332

6.  Injection of Cocaine-Amphetamine Regulated Transcript (CART) peptide into the nucleus accumbens does not inhibit caffeine-induced locomotor activity: Implications for CART peptide mechanism.

Authors:  Martin O Job
Journal:  Pharmacol Biochem Behav       Date:  2016-05-07       Impact factor: 3.533

7.  Levamisole and cocaine synergism: a prevalent adulterant enhances cocaine's action in vivo.

Authors:  Christopher S Tallarida; Erin Egan; Gissel D Alejo; Robert Raffa; Ronald J Tallarida; Scott M Rawls
Journal:  Neuropharmacology       Date:  2014-01-15       Impact factor: 5.250

8.  Inhibition of basal and amphetamine-stimulated extracellular signal-regulated kinase (ERK) phosphorylation in the rat forebrain by muscarinic acetylcholine M4 receptors.

Authors:  Nan He; Li-Min Mao; Adrian W Sturich; Dao-Zhong Jin; John Q Wang
Journal:  Brain Res       Date:  2018-03-22       Impact factor: 3.252

9.  Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change.

Authors:  Gianluigi Tanda; Su Min Li; Maddalena Mereu; Alexandra M Thomas; Aaron L Ebbs; Lauren E Chun; Valeria Tronci; Jennifer L Green; Mu-Fa Zou; Theresa A Kopajtic; Amy Hauck Newman; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2013-04-24       Impact factor: 4.530

Review 10.  Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction.

Authors:  Richard B Rothman; Michael H Baumann; Thomas E Prisinzano; Amy Hauck Newman
Journal:  Biochem Pharmacol       Date:  2007-08-09       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.